Rate control has long been the default strategy for atrial fibrillation, reserving rhythm control primarily for symptom management. In this episode, we examine the EAST-AFNET 4 trial and the evidence supporting early rhythm control as a means to reduce stroke and cardiovascular death in patients diagnosed within the past year. We discuss how timely initiation of anti arrhythmic therapy or catheter ablation differs fundamentally from delayed rhythm strategies studied in earlier trials. The episode explores why these findings challenge longstanding practice patterns and how they may redefine standard care for newly diagnosed atrial fibrillation, even in minimally symptomatic patients.